SEVELAMER HYDROCHLORIDE VERSUS ALUMINUM HYDROXIDE: EFFECT ON SERUM PHOSPHORUS AND LIPIDS IN CAPD PATIENTS

with SH in phase B (p = NS). Moreover, SH administration was associated with a 10.5% ± 9.4% and a 20.1% ± 6.8% fall in total cholesterol (p < 0.05) and low-density lipoprotein cholesterol (p < 0.001) in phase A, and 11.9% ± 7.2% (p < 0.05) and 21.5% ± 2.4% (p < 0.001), respectively, in phase B. In both phases of the study, AH administration was not followed by a significant change in serum lipid parameters. ⇔ Conclusion: Sevelamer hydrochloride is a well-tolerated alternative to calcium- or aluminum-containing phosphorus binder in the control of serum phosphorus in CAPD patients. Furthermore, SH improves the lipid profile in these patients.